perrigo co. plc - PRGO
PRGO
Close Chg Chg %
27.00 0.01 0.02%
Closed Market
27.01
+0.01 (0.02%)
Volume: 2.55M
Last Updated:
May 12, 2025, 3:59 PM EDT
Company Overview: perrigo co. plc - PRGO
PRGO Key Data
| Open $27.38 | Day Range 26.82 - 27.90 |
| 52 Week Range 23.14 - 31.17 | Market Cap $3.71B |
| Shares Outstanding 137.48M | Public Float 136.86M |
| Beta 0.45 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.27 |
| Yield 413.92% | Dividend $0.29 |
| EX-DIVIDEND DATE May 30, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.41M |
PRGO Performance
| 1 Week | -0.07% | ||
| 1 Month | 9.54% | ||
| 3 Months | 10.21% | ||
| 1 Year | -12.11% | ||
| 5 Years | -48.84% |
PRGO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About perrigo co. plc - PRGO
Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
PRGO At a Glance
Perrigo Co. Plc
The Sharp Building
Dublin, Dublin 2/74
| Phone | 353-1-709-4000 | Revenue | 4.37B | |
| Industry | Pharmaceuticals: Major | Net Income | -171,800,000.00 | |
| Sector | Health Technology | Employees | 8,379 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PRGO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.808 |
| Price to Book Ratio | 0.812 |
| Price to Cash Flow Ratio | 9.734 |
| Enterprise Value to EBITDA | 10.518 |
| Enterprise Value to Sales | 1.549 |
| Total Debt to Enterprise Value | 0.561 |
PRGO Efficiency
| Revenue/Employee | 521,983.53 |
| Income Per Employee | -20,503.64 |
| Receivables Turnover | 6.374 |
| Total Asset Turnover | 0.428 |
PRGO Liquidity
| Current Ratio | 2.377 |
| Quick Ratio | 1.341 |
| Cash Ratio | 0.535 |
PRGO Profitability
| Gross Margin | 35.277 |
| Operating Margin | 7.273 |
| Pretax Margin | -1.845 |
| Net Margin | -3.928 |
| Return on Assets | -1.571 |
| Return on Equity | -3.537 |
| Return on Total Capital | -1.979 |
| Return on Invested Capital | -1.934 |
PRGO Capital Structure
| Total Debt to Total Equity | 87.968 |
| Total Debt to Total Capital | 46.80 |
| Total Debt to Total Assets | 39.385 |
| Long-Term Debt to Equity | 86.482 |
| Long-Term Debt to Total Capital | 46.009 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Perrigo Co. Plc - PRGO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.14B | 4.45B | 4.66B | 4.37B | |
Sales Growth
| -18.21% | +7.47% | +4.60% | -6.04% | |
Cost of Goods Sold (COGS) incl D&A
| 2.72B | 2.99B | 2.98B | 2.83B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 312.20M | 338.60M | 359.50M | 325.90M | |
Depreciation
| 102.20M | 86.20M | 93.70M | 97.40M | |
Amortization of Intangibles
| 210.00M | 252.40M | 265.80M | 228.50M | |
COGS Growth
| -16.24% | +9.82% | -0.51% | -4.87% | |
Gross Income
| 1.42B | 1.46B | 1.68B | 1.54B | |
Gross Income Growth
| -21.73% | +2.96% | +15.08% | -8.12% | |
Gross Profit Margin
| +34.23% | +32.79% | +36.07% | +35.28% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.19B | 1.29B | 1.40B | 1.22B | |
Research & Development
| 122.00M | 123.10M | 122.50M | 112.20M | |
Other SG&A
| 1.07B | 1.16B | 1.27B | 1.11B | |
SGA Growth
| -11.58% | +7.86% | +8.61% | -12.33% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 177.60M | 140.40M | 97.30M | 173.10M | |
EBIT after Unusual Expense
| 47.20M | 32.60M | 184.90M | 145.00M | |
Non Operating Income/Expense
| 332.00M | (26.40M) | 31.50M | 22.80M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| (1.10M) | (1.50M) | (1.90M) | (1.50M) | |
Interest Expense
| 120.50M | 145.30M | 224.70M | 248.50M | |
Interest Expense Growth
| -15.14% | +20.58% | +54.65% | +10.59% | |
Gross Interest Expense
| 120.50M | 145.30M | 224.70M | 248.50M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 258.70M | (139.10M) | (8.30M) | (80.70M) | |
Pretax Income Growth
| +273.16% | -153.77% | +94.03% | -872.29% | |
Pretax Margin
| +6.25% | -3.13% | -0.18% | -1.85% | |
Income Tax
| 389.60M | (8.20M) | (3.90M) | 80.00M | |
Income Tax - Current - Domestic
| 14.90M | (7.80M) | 18.20M | 30.40M | |
Income Tax - Current - Foreign
| 384.90M | 33.60M | 58.60M | 59.30M | |
Income Tax - Deferred - Domestic
| 3.30M | (8.60M) | (12.90M) | 27.60M | |
Income Tax - Deferred - Foreign
| (13.50M) | (25.40M) | (67.80M) | (37.30M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| (1.10M) | (1.50M) | (1.90M) | (1.50M) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (130.90M) | (130.90M) | (4.40M) | (160.70M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (130.90M) | (130.90M) | (4.40M) | (160.70M) | |
Net Income Growth
| - | +19.50% | +96.64% | -3,552.27% | |
Net Margin Growth
| -3.16% | -2.94% | -0.09% | -3.67% | |
Extraordinaries & Discontinued Operations
| 14.50M | (9.70M) | (8.30M) | (11.10M) | |
Discontinued Operations
| 14.50M | (9.70M) | (8.30M) | (11.10M) | |
Net Income After Extraordinaries
| (116.40M) | (140.60M) | (12.70M) | (171.80M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (116.40M) | (140.60M) | (12.70M) | (171.80M) | |
EPS (Basic)
| -0.8713 | -1.0454 | -0.0939 | -1.2504 | |
EPS (Basic) Growth
| +27.07% | -19.98% | +91.02% | -1,231.63% | |
Basic Shares Outstanding
| 133.60M | 134.50M | 135.30M | 137.40M | |
EPS (Diluted)
| -0.8713 | -1.0454 | -0.0939 | -1.2504 | |
EPS (Diluted) Growth
| +27.07% | -19.98% | +91.02% | -1,231.63% | |
Diluted Shares Outstanding
| 133.60M | 134.50M | 135.30M | 137.40M | |
EBITDA
| 537.00M | 511.60M | 641.70M | 644.00M | |
EBITDA Growth
| -36.59% | -4.73% | +25.43% | +0.36% | |
EBITDA Margin
| +12.97% | +11.50% | +13.78% | +14.72% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 34.50 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.59 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 3.02 | |
| Last Quarter’s Earnings | 0.60 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.57 | Next Fiscal Year Estimate | 3.268 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 5 | 5 |
| Mean Estimate | 0.59 | 0.80 | 3.02 | 3.27 |
| High Estimates | 0.62 | 0.84 | 3.06 | 3.31 |
| Low Estimate | 0.55 | 0.75 | 2.97 | 3.23 |
| Coefficient of Variance | 5.36 | 4.89 | 1.17 | 1.15 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Perrigo Co. Plc - PRGO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Perrigo Co. Plc - PRGO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 9, 2025 | Abbie Lennox EVP and CSO | 9,553 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 41,530 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,092,654.30 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 67,260 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,769,610.60 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 40,451 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,064,265.81 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 11,464 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 36,373 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 956,973.63 |
| Apr 8, 2025 | Robert Willis EVP & CHRO | 4,140 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 35,668 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 19,108 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Patrick Lockwood-Taylor CEO; Director | 73,708 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,939,257.48 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 6,670 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 175,487.70 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 5,414 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Catherine C. B. Schmelter EVP & President CSCA | 8,310 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 218,636.10 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 12,738 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 8, 2025 | Eduardo Guarita Bezerra EVP & Chief Financial Officer | 45,655 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 1,201,183.05 |
| Apr 8, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 35,558 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.31 per share | 935,530.98 |
| Mar 11, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 42,159 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $28.68 per share | 1,209,120.12 |
| Mar 11, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 39,859 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $27.76 per share | 1,106,485.84 |
| Mar 11, 2025 | Ronald C. Janish EVP, Gbl Ops & SC & CTO | 6,755 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |